Cargando…

The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients

Background: Anti-epidermal-growth-factor-receptor (EGFR) therapies in combination with radiotherapy are being studied on de-escalation clinical trials for HPV-related oropharyngeal cancer (OPC) patients. The HPV16-E5 oncoprotein increases recycling of activated EGFR to the cell surface, enhancing fa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taberna, Miren, Torres, Montserrat, Alejo, María, Mena, Marisa, Tous, Sara, Marquez, Sandra, Pavón, Miquel A., León, Xavier, García, Jacinto, Guix, Marta, Hijano, Rafael, Bonfill, Teresa, Aguilà, Antón, Lozano, Alicia, Mesía, Ricard, Alemany, Laia, Bravo, Ignacio G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297752/ https://www.ncbi.nlm.nih.gov/pubmed/30619735 http://dx.doi.org/10.3389/fonc.2018.00589

Ejemplares similares

HPV-relatedness definitions for classifying HPV-related oropharyngeal cancer patient do impact on TNM classification and patients’ survival
por: Taberna, Miren, et al.
Publicado: (2018)

Epidemiology of human papillomavirus-related oropharyngeal cancer in a classically low-burden region of southern Europe
por: Mena, M., et al.
Publicado: (2020)

Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas
por: Rai, Ashutosh, et al.
Publicado: (2021)

Immunohistochemical analysis of ADAMTS-1, versican and pEGFR expressions in periapical granuloma and radicular cyst
por: Batista, Nádia Marielly Gomes, et al.
Publicado: (2021)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

Might Oral Human Papillomavirus (HPV) Infection in Healthy Individuals Explain Differences in HPV-Attributable Fractions in Oropharyngeal Cancer? A Systematic Review and Meta-analysis
por: Mena, Marisa, et al.
Publicado: (2019)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

Correlation of EGFR, pEGFR and p16(INK4) expressions and high risk HPV infection in HIV/AIDS-related squamous cell carcinoma of conjunctiva
por: Mwololo, Anthony, et al.
Publicado: (2014)

Concordance of p16(INK4a) and E6*I mRNA among HPV-DNA-Positive Oropharyngeal, Laryngeal, and Oral Cavity Carcinomas from the ICO International Study
por: Mena, Marisa, et al.
Publicado: (2022)

Retraction: Down-regulation of the radiation-induced pEGFR(Thr654) mediated activation of DNA-PK by Cetuximab in cervical cancer cells
por: Fisher, Laura
Publicado: (2021)

Human papillomavirus in premalignant oral lesions: No evidence of association in a Spanish cohort
por: Gomez-Armayones, Sara, et al.
Publicado: (2019)

Retracted Article: Down-regulation of the radiation-induced pEGFR(Thr654) mediated activation of DNA-PK by Cetuximab in cervical cancer cells
por: Qi, Yunxiang, et al.
Publicado: (2020)

The Multidisciplinary Team (MDT) Approach and Quality of Care
por: Taberna, Miren, et al.
Publicado: (2020)

EGFR as a biomarker of smoking status and survival in oropharyngeal squamous cell carcinoma
por: Sivarajah, Shanmugappiriya, et al.
Publicado: (2019)

A Straightforward HPV16 Lineage Classification Based on Machine Learning
por: Asensio-Puig, Laura, et al.
Publicado: (2022)

Inhibition of GRP78 abrogates radioresistance in oropharyngeal carcinoma cells after EGFR inhibition by cetuximab
por: Sun, Chaonan, et al.
Publicado: (2017)

Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
por: Morán, Teresa, et al.
Publicado: (2018)

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
por: Oliva, M, et al.
Publicado: (2019)

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
por: Morán, Teresa, et al.
Publicado: (2019)

Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
por: Arribas, Lorena, et al.
Publicado: (2021)

Expression patterns of uPAR, TF and EGFR and their potential as targets for molecular imaging in oropharyngeal squamous cell carcinoma
por: Christensen, Anders, et al.
Publicado: (2022)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR
por: Wang, Anbang, et al.
Publicado: (2020)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity
por: Jun, Sei-Yong, et al.
Publicado: (2022)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58
por: de Sanjosé, Silvia, et al.
Publicado: (2019)

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
por: Wu, Shang-Gin, et al.
Publicado: (2011)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
por: Kuiper, J L, et al.
Publicado: (2016)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Impact of a single eGFR and eGFR-estimating equation on chronic kidney disease reclassification: a cohort study in primary care
por: Hirst, Jennifer A, et al.
Publicado: (2018)

Tenascin turns on the EGFR
por: Jegalian, Karin
Publicado: (2001)

Sweeter tumors with EGFR
por: Robinson, Richard
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_9ppjcapvqcvus2sg0v8lmp3ueb